Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction Results of the EXCELLENT Trial

Overview of attention for article published in JACC: Heart Failure, September 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 4 news outlets
twitter: 1 X user

wikipedia: 1 Wikipedia page

Readers on

mendeley: 2 Mendeley

So far, Altmetric has seen 4 news stories from 4 outlets.

News story from Le Quotidien du Medicin on Wednesday 18 March 2026

Le Quotidien du Medicin, 18 Mar 2026

CellProthera announces peer-reviewed publication of its Phase I/IIb results on safety and feasibility of ProtheraCytes® in patients with severe heart failure post-myocardial Infarction

BioSpace, 23 Sep 2025

JACC-Heart Failure publication highlights high-quality cell expansion, good tolerability, manageable procedural risk and…

News story from Finanz Nachrichten on Monday 22 September 2025

Finanz Nachrichten, 22 Sep 2025

CellProthera announces peer-reviewed publication of its Phase I/IIb results on safety and feasibility of ProtheraCytes® in patients with severe heart failure post-myocardial Infarction

Yahoo! Finance USA, 22 Sep 2025

JACC-Heart Failure publication highlights high-quality cell expansion, good tolerability, manageable procedural risk and…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.